Skip to main content
. Author manuscript; available in PMC: 2021 Oct 5.
Published in final edited form as: FASEB J. 2021 Mar;35(3):e21415. doi: 10.1096/fj.202002540R

FIGURE 9.

FIGURE 9

Effect of deletion or inhibition of SphK1 on blood and liver S1P levels. (A) WT mice treated without or with the SphK1-specific inhibitor SKI-1 (10 mg/kg) or SphK1−/− mice were challenged without (vehicle) or with GalN/LPS for 1 hour. Levels of S1P (A,B) and SK1-I (C,D) were determined by LC-ESI-MS/MS in blood (A,C) or liver (B,D). For A, n = 4-6; for B-D, n = 2 for untreated mice; n = 4 for GalN/LPS-treated mice. Data are mean ± SD. *P < .05 compared to vehicle